A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors

@article{Raez2012API,
  title={A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors},
  author={Luis E. Raez and Kyriakos P. Papadopoulos and Alejandro Daniel Ricart and E. Gabriela Chiorean and Robert S. DiPaola and Mark Stein and Caio Max S Rocha Lima and James J. Schlesselman and Khaled A. Tolba and Virginia K. Langmuir and Stewart Kroll and Don Jung and Metin Kurtoğlu and Joseph D. Rosenblatt and Theodore J. Lampidis},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2012},
  volume={71},
  pages={523-530}
}
PurposeThis phase I trial was initiated to evaluate the safety, pharmacokinetics (PK) and maximum tolerated dose (MTD) of the glycolytic inhibitor, 2-deoxy-d-glucose (2DG) in combination with docetaxel, in patients with advanced solid tumors.MethodsA modified accelerated titration design was used. 2DG was administered orally once daily for 7 days every other week starting at a dose of 2 mg/kg and docetaxel was administered intravenously at 30 mg/m2 for 3 of every 4 weeks beginning on day 1 of… 

Figures and Tables from this paper

2-Deoxy-D-Glucose as an Adjunct to Standard of Care in the Medical Management of COVID-19: A Proof-of-Concept & Dose-Ranging Randomised Clinical Trial
TLDR
2-DG 90 mg/kg/day as adjunct to SOC showed clinical benefits over SOC alone in the treatment of moderate to severe COVID-19 and the promising trends observed in current phase-II study encourage confirmatory evaluation of the efficacy and safety of 2- DG in a larger phase-III trial.
2-Deoxy-d-Glucose Can Complement Doxorubicin and Sorafenib to Suppress the Growth of Papillary Thyroid Carcinoma Cells
TLDR
Tumor cells display a shift in energy metabolism from oxidative phosphorylation to aerobic glycolysis, and the therapeutic effects of low combined doses of 2-DG and doxorubicin or sorafenib are similar to those of high doses of dox orubic in alone or alone in PTC cell lines regardless of the BRAFV600E mutation.
2-Deoxy-D-glucose enhances dichloroacetate antitumor action against Lewis lung carcinoma.
TLDR
2DG significantly enhanced antitumor activity of DCA with accompanying inhibition of glycolysis and increase of cytotoxic activity of CD14(+) cells infiltrating tumor tissue, and could be considered as a promising antimetastatic agent.
Rescue of 2-Deoxyglucose Side Effects by Ketogenic Diet
TLDR
KD reduces the sedative effects of 2-DG and dramatically increases the maximum tolerated dose of 1-deoxyglucose, which is, to the authors' knowledge, the first demonstration of increased tolerance to glycolysis inhibition by KD.
Non-radioactive 2-deoxy-2-fluoro-D-glucose inhibits glucose uptake in xenograft tumours and sensitizes HeLa cells to doxorubicin in vitro
TLDR
Investigation of the use of non-radioactive 2-deoxy-2-fluoro-D-glucose (19FDG) in combination with doxorubicin (Dox) in HeLa cells suggests 19FDG is a promising combination therapy, which may lead to decreased ROS scavenging via glycolysis, and enhanced treatment success.
Co-treatment of breast cancer cells with pharmacologic doses of 2-deoxy-D-glucose and metformin: Starving tumors.
TLDR
Co-treatment with doses of the glycolysis inhibitor 2DG and anti-diabetic drug metformin is tolerable in humans and may be a suitable therapy for human breast cancers.
2-Deoxy-d-Glucose Ameliorates PKD Progression.
TLDR
Investigation of the effects of chronic treatment with low doses of the glucose analog 2-deoxy-d-glucose (2DG) on ADPKD progression in orthologous and slowly progressive murine models created by inducible inactivation of the Pkd1 gene postnatally provides proof of principle support for the use of 2DG as a therapeutic strategy in AD PKD.
2-Deoxy-D-glucose enhances the anti-cancer effects of idarubicin on idarubicin-resistant P388 leukemia cells.
TLDR
The results indicated that P388 cells activated glycolysis after acquiring IDA resistance and therefore, inhibition of the glyCOlytic pathway via 2-DG might be a useful strategy for cancer therapy against IDA- resistant leukemia cells.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 36 REFERENCES
Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas.
Targeting hypoxia, a novel treatment for advanced retinoblastoma.
TLDR
Treatment with glycolytic inhibitors as adjuvants to chemotherapy has the potential to increase the efficacy of chemotherapy in advanced retinoblastoma and may have benefits for children with this disease.
2-Deoxy-d-glucose Increases the Efficacy of Adriamycin and Paclitaxel in Human Osteosarcoma and Non-Small Cell Lung Cancers In Vivo
TLDR
Treatment of tumors with both the glycolytic inhibitor 2-DG and ADR or paclitaxel results in a significant reduction in tumor growth compared with either agent alone, providing a rationale for initiating clinical trials using glyCOlytic inhibitors in combination with chemotherapeutic agents to increase their therapeutic effectiveness.
Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2‐deoxyglucose and etomoxir
TLDR
It is concluded that the long‐term effects of cisplatin potentiation are important and either p53‐independent or improved by a lack of p53, and the strategy holds promise with genotoxic as well non‐genotoxic anticancer drugs.
Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-d-glucose in tumor cells treated under hypoxic vs aerobic conditions
TLDR
The contention that glycolytic inhibitors added to standard chemotherapeutic protocols should increase treatment efficacy by selectively killing the slow-growing cells, which are found in the hypoxic portions of solid tumors, while sparing most of the normal cells that are also slow- growing but are living under aerobic conditions is supported.
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
TLDR
A model by which a combined assessment of all existing lesions, characterized by target lesions and nontarget lesions, is used to extrapolate an overall response to treatment is proposed, which is largely validated by the Response Evaluation Criteria in Solid Tumors Group and integrated into the present guidelines.
New Guidelines to Evaluate the Response to Treatment in Solid Tumors.
TLDR
A model by which a combined assessment of all existing lesions, characterized by target lesions and nontarget lesions, is used to extrapolate an overall response to treatment is proposed, which is largely validated by the Response Evaluation Criteria in Solid Tumors Group and integrated into the present guidelines.
Analysis of cellular sensitization with cisplatin-induced apoptosis by glucose-starved stress in cisplatin-sensitive and -resistant A431 cell line.
TLDR
Results indicated that the glucose-starved stress condition was associated with increased sensitivity to CDDP in the up-regulated GRP78 cells, and the reduction of CDDP-induced apoptosis can be considered as one of the CDDP resistant mechanisms in a glucose- starvation condition.
Cellular sensitization to cisplatin and carboplatin with decreased removal of platinum-DNA adduct by glucose-regulated stress
TLDR
The results indicated that the decreased removal of platinum-DNA adducts was associated with increased sensitivity to cisplatin and carboplatin in the stressed cells.
Hypersensitization of tumor cells to glycolytic inhibitors.
TLDR
In vitro results suggest that glycolytic inhibitors could be used to specifically target the slow-growing cells of a tumor and thereby increase the efficacy of current chemotherapeutic and irradiation protocols designed to kill rapidly dividing cells.
...
1
2
3
4
...